UNSPSC 51141562: Ilepcimide

This classification denotes an anticonvulsant agent with the molecular formula C15H17NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5ML58O200F, chemically known as 1-(3-(1,3-benzodioxol-5-yl)-1-oxo-2-propenyl)piperidine but generally known as ilepcimide, which bears US NIH Compound Identifier 54930. European Medicines Agency schedules Ilepcimide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08130MIG. The term ILEPCIMIDE is an International Non-Proprietary Name.

UNSPSC 51141562 Ilepcimide is a Commodity code under which state and local governments procure pharmaceutical products, though recent opportunities tagged with this code show substantial scope mismatch — the posted solicitations actually involve naloxone, generic multi-source pharmaceuticals, OTC products, and direct-to-manufacturer prescription programs rather than ilepcimide specifically. State and local buyers under this code include county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. The work involves establishing contracts for pharmaceutical supply, including procurement of specific drug products with National Drug Codes, management of distribution through authorized wholesalers, compliance with FDA and Drug Supply Chain Security Act requirements, and negotiation of pricing structures such as flat pricing, net price formats, or WAC-minus models. Issuers range from individual counties to multi-state cooperative purchasing organizations; Seminole County, Florida and the Minnesota Department of Administration's MMCAP are recent examples.

Geographic activity centers on Florida, Texas, and the Upper Midwest, with MMCAP serving participating states including Minnesota and Oregon. Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, response due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford; MMCAP's RFP S1070000015802 (posted January 20, 2026, response due March 26, 2026) to establish multi-award contracts for generic pharmaceuticals and OTC products across participating state and local facilities, with pricing weighted at 75 percent of evaluation and administered through three authorized wholesalers; and the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026, response due April 3, 2026) exploring vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager and wholesaler arrangements. Vendors must carry workers' compensation, commercial general liability (typically $5 million per occurrence), and professional liability insurance; comply with cGMP and DSCSA; and maintain contractual relationships with designated wholesalers where applicable.